Abstract
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide (NO) synthase in-hibitor, inhibits NO synthesis and contributes to the pathogenesis of many human diseases. In adults, ADMA has been identified as a biomarker for chronic kidney disease (CKD) progression and cardiovascular risk. However, little attention is given to translating the adult experience into the pediatric clinical setting. In the current review, we summarize circulating and urinary ADMA reported thus far in clinical studies relating to kidney disease in children and adolescents, as well as systematize the knowledge on pathophysiological role of ADMA in the kidneys. The aim of this review is also to show the various analytical methods for measuring ADMA and the issues tht need to be addressed before transforming to clinical practice in pediatric medicine. The last task is to suggest that ADMA may not only be suitable as a diagnostic or prognostic biomarker, but also a promising therapeutic strategy to treat pediatric kidney disease in the future.
| Original language | English |
|---|---|
| Article number | 837 |
| Journal | Children |
| Volume | 8 |
| Issue number | 10 |
| DOIs | |
| State | Published - 10 2021 |
Bibliographical note
Publisher Copyright:© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Asymmetric dimethylarginine
- Biomarker
- Children
- Dimethylamine
- Dimethylarginine dimethylaminohydrolase
- Kidney disease
- Nitric oxide
- Pediatric nephrology
- Protein arginine methyl transferase
Fingerprint
Dive into the research topics of 'Asymmetric dimethylarginine (ADMA) in pediatric renal diseases: From pathophysiological phenomenon to clinical biomarker and beyond'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver